Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INAB
- Price
- 2.18
- Stock movement up
- +0.05 (2.35%)
- Company name
- In8bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.27M
- Ent value
- 8.64M
- Price/Sales
- 1.41
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -92.73%
- 3 year return
- -67.15%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-06-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INAB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.41 |
| Price to Book | 0.61 |
| EV to Sales | 2.31 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.42M |
| EPS (TTM) | -20.21 |
| FCF per share (TTM) | -16.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.75M |
| Gross profit (TTM) | 1.86M |
| Operating income (TTM) | -31.88M |
| Net income (TTM) | -31.88M |
| EPS (TTM) | -20.21 |
| EPS (1y forward) | -8.82 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 49.57% |
| Operating margin (TTM) | -850.45% |
| Profit margin (TTM) | -850.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.00M |
| Net receivables | 0.00 |
| Total current assets | 6.70M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 15.97M |
| Accounts payable | 1.14M |
| Short/Current long term debt | 5.47M |
| Total current liabilities | 3.63M |
| Total liabilities | 7.38M |
| Shareholder's equity | 8.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -24.97M |
| Capital expenditures (TTM) | 309.00K |
| Free cash flow (TTM) | -25.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -371.16% |
| Return on Assets | -199.64% |
| Return on Invested Capital | -308.96% |
| Cash Return on Invested Capital | -245.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.15 |
| Daily high | 2.23 |
| Daily low | 2.11 |
| Daily Volume | 153K |
| All-time high | 300.00 |
| 1y analyst estimate | 142.50 |
| Beta | -0.07 |
| EPS (TTM) | -20.21 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| INAB | S&P500 | |
| Current price drop from All-time high | -99.27% | -3.04% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 3 Jun 2025 | 9 Mar 2009 |
| Avg drop from high | -78.84% | -11.04% |
| Avg time to new high | 489 days | 12 days |
| Max time to new high | 977 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.27M
Marketcap category
Small-cap
Description
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Employees
39
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page